Oleanolic acid and ursolic acid: Novel hepatitis C virus antivirals that inhibit NS5B activity

Antiviral Research

Volumn 98, Issue 1, 2013, Pages 44-53

  Kong, Lingbao ^a   Li, Shanshan ^b   Liao, Qingjiao ^c   Zhang, Yanni ^a   Sun, Ruina ^a   Zhu, Xiangdong ^a   Zhang, Qinghua ^a   Wang, Jun ^a   Wu, Xiaoyu ^a   Fang, Xiaonan ^d   Zhu, Ying ^e  

^a JIANGXI AGRICULTURAL UNIVERSITY   (China)

^b IOWA STATE UNIVERSITY   (United States)

^c WUHAN INSTITUTE OF VIROLOGY   (China)

^d TONGJI UNIVERSITY SCHOOL OF MEDICINE   (China)

^e WUHAN UNIVERSITY   (China)

Author keywords

Antivirals; HCV; NS5B; Oleanolic acid; Ursolic acid

Indexed keywords

ANTIVIRUS AGENT; LIGUSTRUM LUCIDUM EXTRACT; NONSTRUCTURAL PROTEIN 5B; OLEANOLIC ACID; URSOLIC ACID;

ANTIVIRAL ACTIVITY; ARTICLE; ASSAY; CONTROLLED STUDY; GENOTYPE; HEPATITIS C; HEPATITIS C VIRUS; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; MEDICINAL PLANT; NONHUMAN; PRIORITY JOURNAL; REPLICON; VIRUS REPLICATION;

ANTIVIRAL AGENTS; CELL LINE; DOWN-REGULATION; DRUGS, CHINESE HERBAL; HEPACIVIRUS; HEPATITIS C; HUMANS; LIGUSTRUM; OLEANOLIC ACID; REPLICON; TRITERPENES; VIRAL NONSTRUCTURAL PROTEINS; VIRUS REPLICATION;

HEPATITIS C VIRUS;

EID: 84874626512     PISSN: 01663542     EISSN: 18729096     Source Type: Journal    
DOI: 10.1016/j.antiviral.2013.02.003     Document Type: Article

References (36)

1. Ahmed-Belkacem A., Ahnou N., Barbotte L., Wychowski C., Pallier C., Brillet R., Pohl R.T., Pawlotsky J.M. Silibinin and related compounds are direct inhibitors of hepatitis C virus RNA-dependent RNA polymerase. Gastroenterology 2010, 138:1112-1122.
2. Assis D.N., Lim J.K. New pharmacotherapy for hepatitis C. Clin. Pharmacol. Ther. 2012, 92:294-305.
3. Bachhav S.S., Patil S.D., Bhutada M.S., Surana S.J. Oleanolic acid prevents glucocorticoid-induced hypertension in rats. Phytother. Res. 2011, 25:1435-1439.
4. Behrens S.E., Tomei L., De Francesco R. Identification and properties of the RNA-dependent RNA polymerase of hepatitis C virus. EMBO J. 1996, 15:12-22.
5. Chen L., Zhang Y., Kong X., Peng S., Tian J. Synthesis and biological evaluation of nitric oxide-releasing derivatives of oleanolic acid as inhibitors of HepG2 cell apoptosis. Bioorg. Med. Chem. Lett. 2007, 17:2979-2982.
6. Chinese Materia Medica 1999, vol. 6. Committee of Chinese Materia Medica, Shanghai Science and Technology Press, pp. 183-189.
7. Pharmacopoeia of PR China 2000, Committee of National Pharmacopoeia, Press of Chemical Industry, Beijing, p. 34.
8. De Re V. Interferon-based therapy for chronic hepatitis C: current and future perspectives. Hepat. Mon. 2010, 10:231-232.
9. Frese M., Schwarzle V., Barth K., Krieger N., Lohmann V., Mihm S., Haller O., Bartenschlager R. Interferon-gamma inhibits replication of subgenomic and genomic hepatitis C virus RNAs. Hepatology 2002, 35:694-697.
10. Fujiwara Y., Komohara Y., Kudo R., Tsurushima K., Ohnishi K., Ikeda T., Takeya M. Oleanolic acid inhibits macrophage differentiation into the M2 phenotype and glioblastoma cell proliferation by suppressing the activation of STAT3. Oncol. Rep. 2011, 26:1533-1537.
11. Hiasa Y., Kuzuhara H., Tokumoto Y., Konishi I., Yamashita N., Matsuura B., Michitaka K., Chung R.T., Onji M. Hepatitis C virus replication is inhibited by 22β-methoxyolean-12-ene-3β, 24(4β)-diol (ME3738) through enhancing interferon-β. Hepatology 2008, 48:59-69.
12. Hou W., Tian Q., Zheng J., Bonkovsky H.L. MicroRNA-196 represses Bach1 protein and hepatitis C virus gene expression in human hepatoma cells expressing hepatitis C viral proteins. Hepatology 2010, 51:1494-1504.
13. Hudson J.B. Plant photosensitizers with antiviral properties. Antiviral Res. 1989, 12:55-74.
14. Ip P.P., Nijman H.W., Wilschut J., Daemen T. Therapeutic vaccination against chronic hepatitis C virus infection. Antiviral Res. 2012, 96:36-50.
15. Jefferies C.A., Fitzgerald K.A. Interferon gene regulation: not all roads lead to Tolls. Trends Mol. Med. 2005, 11:403-411.
16. Kong L., Li S., Han X., Xiang Z., Fang X., Li B., Wang W., Zhong H., Gao J., Ye L. Inhibition of HCV RNA-dependent RNA polymerase activity by aqueous extract from Fructus Ligustri Lucidi. Virus Res. 2007, 128:9-17.
17. Li S., Yu X., Guo Y., Kong L. Interaction networks of hepatitis C virus NS4B: implications for antiviral therapy. Cell. Microbiol. 2012, 14:994-1002.
18. Liang T.J., Rehermann B., Seeff L.B., Hoofnagle J.H. Pathogenesis, natural history, treatment, and prevention of hepatitis C. Ann. Intern. Med. 2000, 132:296-305.
19. Lin H.M., Yen F.L., Ng L.T., Lin C.C. Protective effects of Ligustrum lucidum fruit extract on acute butylated hydroxytoluene-induced oxidative stress in rats. J. Ethnopharmacol. 2007, 111:129-136.
20. Lindenbach B.D., Evans M.J., Syder A.J., Wolk B., Tellinghuisen T.L., Liu C.C., Maruyama T., Hynes R.O., Burton D.R., McKeating J.A., Rice C.M. Complete replication of hepatitis C virus in cell culture. Science 2005, 309:623-626.
21. Lindenbach B.D., Rice C.M. Unravelling hepatitis C virus replication from genome to function. Nature 2005, 436:933-938.
22. Martin-Aragon S., de las Heras B., Sanchez-Reus M.I., Benedi J. Pharmacological modification of endogenous antioxidant enzymes by ursolic acid on tetrachloride-induced liver damage in rats and primary cultures of rat hepatocytes. Exp. Toxicol. Pathol. 2001, 53:199-206.
23. Mengoni F., Lichtner M., Battinelli L., Marzi M., Mastroianni C.M., Vullo V., Mazzanti G. In vitro anti-HIV activity of oleanolic acid on infected human mononuclear cells. Planta Med. 2002, 68:111-114.
24. Morishima C., Shuhart M.C., Wang C.C., Paschal D.M., Apodaca M.C., Liu Y., Sloan D.D., Graf T.N., Oberlies N.H., Lee D.Y., Jerome K.R., Polyak S.J. Silymarin inhibits in vitro T-cell proliferation and cytokine production in hepatitis C virus infection. Gastroenterology 2010, 138:671-681. 681.e671-672.
25. Pawlotsky J.M. Treatment failure and resistance with direct-acting antiviral drugs against hepatitis C virus. Hepatology 2011, 53:1742-1751.
26. Pham L.V., Ngo H.T., Lim Y.S., Hwang S.B. Hepatitis C virus non-structural 5B protein interacts with cyclin A2 and regulates viral propagation. J. Hepatol. 2012, 57:960-966.
27. Rai R., Deval J. New opportunities in anti-hepatitis C virus drug discovery: targeting NS4B. Antiviral Res. 2011, 90:93-101.
28. Rehman S., Ashfaq U.A., Javed T. Antiviral drugs against hepatitis C virus. Genet. Vaccines Ther. 2011, 9:11.
29. Rice C.M. New insights into HCV replication: potential antiviral targets. Top Antivir. Med. 2011, 19:117-120.
30. Wakita T., Pietschmann T., Kato T., Date T., Miyamoto M., Zhao Z., Murthy K., Habermann A., Krausslich H.G., Mizokami M., Bartenschlager R., Liang T.J. Production of infectious hepatitis C virus in tissue culture from a cloned viral genome. Nat. Med. 2005, 11:791-796.
31. Wang M., Ng K.K.-S., Cherney M.M., Chan L., Yannopoulos C.G., Bedard J., Morin N., Nguyen-Ba N., Alaoui-Ismaili M.H., Bethell R.C., James M.N.G. Non-nucleoside analogue inhibitors bind to an allosteric site on HCV NS5B polymerase: crystal strucutres and mechanism of inhibition. J. Biol. Chem. 2003, 278:9489-9495.
32. Waris G., Sarker S., Siddiqui A. Two-step affinity purification of the hepatitis C virus ribonucleoprotein complex. RNA 2004, 10:321-329.
33. Wu Y., Liao Q., Yang R., Chen X. A novel luciferase and GFP dual reporter virus for rapid and convenient evaluation of hepatitis C virus replication. Virus Res. 2011, 155:406-414.
34. Ye L., Timani K.A., Kong L., Yang X., Liao Q., Wu J. Two cis-acting elements in negative RNA strand of Hepatitis C virus involved in synthesis of positive RNA strand in vitro. Acta Virol. 2005, 49:83-90.
35. Zeuzem S. Interferon-based therapy for chronic hepatitis C: current and future perspectives. Nat. Clin. Pract. Gastroenterol. Hepatol. 2008, 5:610-622.
36. Zhong J., Gastaminza P., Cheng G., Kapadia S., Kato T., Burton D.R., Wieland S.F., Uprichard S.L., Wakita T., Chisari F.V. Robust hepatitis C virus infection in vitro. Proc. Natl. Acad. Sci. USA 2005, 102:9294-9299.